First Light Asset Management LLC raised its holdings in Shire PLC (NASDAQ:SHPG) by 126.1% in the 1st quarter, Holdings Channel reports. The firm owned 179,976 shares of the biopharmaceutical company’s stock after purchasing an additional 100,369 shares during the quarter. Shire accounts for approximately 5.9% of First Light Asset Management LLC’s portfolio, making the stock its 5th largest position. First Light Asset Management LLC’s holdings in Shire were worth $26,887,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. SeaCrest Wealth Management LLC bought a new position in Shire in the 4th quarter valued at $107,000. Amica Retiree Medical Trust bought a new position in Shire in the 4th quarter valued at $120,000. Avestar Capital LLC bought a new stake in shares of Shire during the fourth quarter worth $116,000. Sawtooth Solutions LLC bought a new stake in shares of Shire during the fourth quarter worth $200,000. Finally, Resources Investment Advisors Inc. raised its position in shares of Shire by 70.2% during the first quarter. Resources Investment Advisors Inc. now owns 1,540 shares of the biopharmaceutical company’s stock worth $230,000 after acquiring an additional 635 shares during the last quarter. Hedge funds and other institutional investors own 18.19% of the company’s stock.
Shares of Shire opened at $162.25 on Thursday, MarketBeat Ratings reports. The company has a quick ratio of 0.66, a current ratio of 1.14 and a debt-to-equity ratio of 0.45. Shire PLC has a 12 month low of $123.73 and a 12 month high of $177.51. The firm has a market cap of $48.78 billion, a P/E ratio of 10.71, a P/E/G ratio of 1.33 and a beta of 1.29.
A number of equities research analysts have recently weighed in on SHPG shares. Sanford C. Bernstein upgraded Shire from a “market perform” rating to an “outperform” rating in a research report on Wednesday, February 14th. Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Royal Bank of Canada restated a “buy” rating on shares of Shire in a research report on Thursday, February 15th. B. Riley dropped their target price on Shire from $201.00 to $181.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Finally, JPMorgan Chase & Co. downgraded Shire from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $200.00 to $150.00 in a research report on Monday, February 19th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $201.64.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.